Hypertrophic Cardiomyopathy Medical Society

Our page has moved! Follow us at
https://bit.ly/4a2bcpN

Registration for our 2026 Scientific Sessions is open: hcmsociety.org

Save the date for the HCMS 2026 Scientific Sessions November 6, 2026 in Chicago. Registration open soon!

The New HCM Society

In the Thick of It podcast episode 36: Long-Term Realities: Managing Disease Progression and ICD Selection in Young Patients. Sponsored by Cytokinetics

Patient advocates Hannah and Bethany Keime from HeartCharged sit down with Dr. John Fritzlen to discuss the long-term journey of living with hypertrophic cardiomyopathy (HCM).

The conversation covers the progressive nature of the condition and tailored approaches for counseling young or newly diagnosed patients:

❤️ Onset of heart failure symptoms
❤️ Atrial fibrillation
❤️ Myocardial remodeling
❤️ Benefits of CPET
❤️ Importance of active lifestyle management
❤️ Proactive treatment strategies
❤️ Implantable cardioverter-defibrillators
❤️ Subcutaneous & extravascular systems for younger populations

Watch the session on YouTube: https://bit.ly/4u42HBP

Learn more: https://hcmsociety.org/

Reevaluating Beta Blockers: New Evidence in Non-Obstructive HCM Care is the latest episode in Season 4 of “In the Thick of It,” an HCMS podcast sponsored by Cytokinetics.

Visit the link in the comments to watch the episode.

Dr. Florian Rader joins Dr. Louise Bjerregaard to discuss a groundbreaking randomized, double-blind, triple-crossover trial that challenges the long-standing "mantra" of using beta blockers as first-line therapy for non-obstructive hypertrophic cardiomyopathy (HCM).

This episode is essential listening for clinicians looking to move beyond expert opinion toward evidence-based, personalized care for their non-obstructive HCM patients.

The ODYSSEY Continues: Deep Diving into Non-Obstructive
HCM Data - Sponsored by Cytokinetics

Dr. James MacNamara welcomes Dr. Milind Desai from the Cleveland Clinic to dissect the results and implications of the ODYSSEY trial, the largest randomized trial ever conducted in hypertrophic cardiomyopathy (HCM).

The trial investigated the use of mavacamten in patients with non-obstructive HCM, a population with significant unmet medical needs.

Follow the link in the comments to listen. 👇

HCMS Podcast Episode 34: The Personalized Heart: Moving beyond the 15mm Rule in HCM Diagnosis – Sponsored by Cytokinetics

Dr. John Fritzlen sits down with Dr. Hunain Shiwani to discuss a paradigm shift in diagnosing hypertrophic cardiomyopathy (HCM).

For 50 years, the medical community has relied on a static 15mm wall thickness threshold that fails to account for individual body size, age, and biological s*x; a bias that often leaves female patients underdiagnosed.

How do demographic-based thresholds reduce diagnostic bias, and empower clinicians through tools like the HCM Calculator to provide more equitable care for patients on the margins of traditional criteria?

Follow the link in the comments to learn the answer.⬇️